SCHEMBL12737809

SCHEMBL12737809

CCOC(=O)C1(C)CCOc2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
GLA P06280 1/20 0.42
MAPT P10636 1/20 0.42
GAA P10253 2/20 0.41
OPRM1 P35372 5/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
OPRD1 P41143 3/20 0.40
OPRK1 P41145 3/20 0.40
SLC22A1 O15245 1/20 0.40
SLC6A4 P31645 1/20 0.40
ADRA1A P35348 1/20 0.40
KCNH2 Q12809 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
POLB P06746 1/20 0.40
GRM1 Q13255 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25871760 0.84 SMN1; SMN2 (0.45) ALDH1A1GLAMAPTGAAOPRM1
SCHEMBL10284783 0.82 ALDH1A1 (0.40) ALDH1A1GLAMAPTGAAOPRM1
SCHEMBL31110938 0.80 KMT2A (0.39) ALDH1A1MAPTGAASMN1; SMN2KDM4E
SCHEMBL18159806 0.79 RARA (0.40) ALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL17107547 0.79 BACE1 (0.39) ALDH1A1GLAMAPTGAASMN1; SMN2
SCHEMBL5477166 0.78 GAA (0.47) ALDH1A1GLAGAAKCNH2
SCHEMBL11075478 0.77 OPRM1 (0.44) OPRM1SMN1; SMN2OPRD1OPRK1SLC22A1
SCHEMBL19716108 0.74 ATM (0.44) OPRM1SMN1; SMN2POLBCYP2C9TSHR
SCHEMBL17922547 0.74 SIGMAR1 (0.40) ALDH1A1GRM1BLMPMP22KDM4E
SCHEMBL20997323 0.74 SIGMAR1 (0.40) ALDH1A1GRM1BLMPMP22KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082107-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC. 2011-04-07 US disclosed
US-7807700-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 AMGEN INC. (US) 2010-10-05 US disclosed
US-20080045503-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082107-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD3B1, HSD17B1 ALDH1A1 100/4885GLA 983/4885MAPT 3588/4885
US-20080045503-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD3B1, HSD17B1 ALDH1A1 100/4885GLA 983/4885MAPT 3588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.